Michael D. Iseman

13.9k total citations · 4 hit papers
72 papers, 9.3k citations indexed

About

Michael D. Iseman is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Michael D. Iseman has authored 72 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Infectious Diseases, 40 papers in Epidemiology and 20 papers in Surgery. Recurrent topics in Michael D. Iseman's work include Tuberculosis Research and Epidemiology (38 papers), Mycobacterium research and diagnosis (35 papers) and Infectious Diseases and Tuberculosis (11 papers). Michael D. Iseman is often cited by papers focused on Tuberculosis Research and Epidemiology (38 papers), Mycobacterium research and diagnosis (35 papers) and Infectious Diseases and Tuberculosis (11 papers). Michael D. Iseman collaborates with scholars based in United States, Netherlands and Australia. Michael D. Iseman's co-authors include C. Robert Horsburgh, Gwen A. Huitt, Kevin Winthrop, Charles L. Daley, Alastair J.J. Wood, David E. Griffith, Fred M. Gordin, Antonino Catanzaro, Richard J. Wallace and Timothy R. Aksamit and has published in prestigious journals such as New England Journal of Medicine, JAMA and Annals of Internal Medicine.

In The Last Decade

Michael D. Iseman

71 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

2007 4.3k citations David E. Griffith, Timothy R. Aksamit et al. American Journal of Respiratory and Critical Care Medicine profile →
Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin

1993 550 citations Marian Goble, Michael D. Iseman et al. profile →
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis

2005 543 citations Svetlana Gelperina, Kevin O. Kisich et al. American Journal of Respiratory and Critical Care Medicine profile →
Treatment of Multidrug-Resistant Tuberculosis

1993 537 citations Michael D. Iseman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael D. Iseman United States	35	7.0k	5.8k	2.4k	2.4k	1.1k	72	9.3k
Antonino Catanzaro United States	38	8.3k 1.2×	7.1k 1.2×	1.9k 0.8×	2.4k 1.0×	1.1k 1.0×	138	10.6k
C. Fordham von Reyn United States	40	8.0k 1.1×	6.5k 1.1×	2.2k 0.9×	2.5k 1.1×	598 0.6×	129	10.1k
Gail L. Woods United States	44	5.6k 0.8×	5.1k 0.9×	1.8k 0.7×	1.2k 0.5×	501 0.5×	196	8.8k
David E. Griffith United States	53	10.0k 1.4×	7.2k 1.2×	1.8k 0.7×	4.7k 2.0×	1.8k 1.6×	173	12.2k
Kenneth N. Olivier United States	48	9.3k 1.3×	6.2k 1.1×	1.7k 0.7×	4.3k 1.8×	3.0k 2.8×	148	12.5k
B. Dupont France	53	6.2k 0.9×	6.7k 1.2×	461 0.2×	1.1k 0.4×	460 0.4×	191	9.3k
Nina Singh United States	54	8.1k 1.2×	5.9k 1.0×	1.5k 0.6×	473 0.2×	589 0.5×	162	10.5k
Richard J. Hamill United States	48	7.9k 1.1×	8.1k 1.4×	1.8k 0.8×	374 0.2×	430 0.4×	109	11.6k
Arunaloke Chakrabarti India	61	7.0k 1.0×	10.8k 1.9×	422 0.2×	1.6k 0.7×	2.8k 2.6×	400	14.4k
George A. Sarosi United States	49	5.3k 0.8×	2.8k 0.5×	2.6k 1.1×	385 0.2×	1.6k 1.4×	242	10.2k

Countries citing papers authored by Michael D. Iseman

Since Specialization

Citations

This map shows the geographic impact of Michael D. Iseman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Iseman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Iseman more than expected).

Fields of papers citing papers by Michael D. Iseman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Iseman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Iseman. The network helps show where Michael D. Iseman may publish in the future.

Co-authorship network of co-authors of Michael D. Iseman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Iseman. A scholar is included among the top collaborators of Michael D. Iseman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Iseman. Michael D. Iseman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morgenstern, David, et al.. (2016). Comparing the temporal colonization and microbial diversity of showerhead biofilms in Hawai'i and Colorado. FEMS Microbiology Letters. 363(4). fnw005–fnw005. 6 indexed citations

Albert, Richard, John A. Sbarbaro, Leonard D. Hudson, & Michael D. Iseman. (2015). High-Dose Ethambutol: Its Role in Intermittent Chemotherapy. American Review of Respiratory Disease.

Winthrop, Kevin & Michael D. Iseman. (2013). Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nature Reviews Rheumatology. 9(9). 524–531. 44 indexed citations

Kartalija, Marinka, Alida R. Ovrutsky, Gregory B. Pott, et al.. (2012). Patients with Nontuberculous Mycobacterial Lung Disease Exhibit Unique Body and Immune Phenotypes. American Journal of Respiratory and Critical Care Medicine. 187(2). 197–205. 169 indexed citations

Mauchley, David, Charles L. Daley, Michael D. Iseman, & John D. Mitchell. (2012). Pulmonary Resection and Lung Transplantation for Bronchiectasis. Clinics in Chest Medicine. 33(2). 387–396. 5 indexed citations

Ingen, Jakko van, Martin J. Boeree, Dick van Soolingen, et al.. (2011). Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?. Infection Genetics and Evolution. 12(4). 832–837. 26 indexed citations

Nick, Jerry A., Robert L. Young, David P. Nichols, et al.. (2010). Effects of Gender and Age at Diagnosis on Disease Progression in Long-term Survivors of Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 182(5). 614–626. 86 indexed citations

Chan, Edward D. & Michael D. Iseman. (2010). Slender, Older Women Appear to Be More Susceptible to Nontuberculous Mycobacterial Lung Disease. Gender Medicine. 7(1). 5–18. 101 indexed citations

Griffith, David E., Timothy R. Aksamit, Barbara A. Brown‐Elliott, et al.. (2007). An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. American Journal of Respiratory and Critical Care Medicine. 175(4). 367–416. 4257 indexed citations breakdown →

10.

Gelperina, Svetlana, Kevin O. Kisich, Michael D. Iseman, & Leonid Heifets. (2005). The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 172(12). 1487–1490. 543 indexed citations breakdown →

11.

Rodman, David M., Sonya L. Heltshe, Marci K. Sontag, et al.. (2005). Late Diagnosis Defines a Unique Population of Long-term Survivors of Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 171(6). 621–626. 119 indexed citations

12.

Chan, Edward D., et al.. (2004). Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 169(10). 1103–1109. 254 indexed citations

13.

Iseman, Michael D.. (2001). A 52-Year-Old Man With a Positive PPD. JAMA. 286(16). 2015–2015. 3 indexed citations

14.

Pomerantz, Marvin, et al.. (1996). Resection of the right middle lobe and lingula for mycobacterial infection. The Annals of Thoracic Surgery. 62(4). 990–993. 37 indexed citations

15.

Elliott, Alison M. & Michael D. Iseman. (1993). THE MEDICAL MANAGEMENT OF DISEASE CAUSED BY DRUG-SUSCEPTIBLE: Mycobacterium tuberculosis. Chest Surgery Clinics of North America. 3(4). 707–713. 1 indexed citations

16.

Madsen, Lorie A. & Michael D. Iseman. (1993). MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS. Chest Surgery Clinics of North America. 3(4). 715–721. 1 indexed citations

17.

Sbarbaro, John A., Michael D. Iseman, & Alfred J. Crowle. (1992). The Combined Effect of Rifampin and Pyrazinamide within the Human Macrophage. American Review of Respiratory Disease. 146(6). 1448–1451. 14 indexed citations

18.

Hopewell, Philip C., Michael H. Cynamon, Jeffrey R. Starke, Michael D. Iseman, & Richard O’Brien. (1992). Evaluation of New Anti-Infective Drugs for the Treatment of Disease Caused by Mycobacterium kansasii and Other Mycobacteria. Clinical Infectious Diseases. 15(Supplement_1). S307–S312. 4 indexed citations

19.

Gangadharam, P R, et al.. (1987). Activity of Rifabutin Alone or in Combination with Clofazimine or Ethambutol or Both Against Acute and Chronic Experimental Mycobacterium intracellulare Infections. American Review of Respiratory Disease. 136(2). 329–333. 56 indexed citations

20.

Perumal, Veluchamy K., P R Gangadharam, & Michael D. Iseman. (1987). Effect of Rifabutin on the Phagocytosis and Intracellular Growth of Mycobacterium intracellular in Mouse Resident and Activated Peritoneal and Alveolar Macrophages. American Review of Respiratory Disease. 136(2). 334–337. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact